Breakthrough in Cancer Gene Therapy: MDM2-GPX4-Ferroptosis Regulatory Axis Identified

Strategic Insights -

Research led by Tao Liu of Capital Medical University has made a groundbreaking discovery in the field of cancer gene therapy, elucidating the role of the MDM2-GPX4-ferroptosis regulatory axis in intracerebral hemorrhage. This research holds promise for identifying new therapies for this condition, which is characterized by bleeding in the brain.

The study, published in the Neural Regeneration Research journal, involved the creation of an in vitro intracerebral hemorrhage model using BV2 microglial cells. The researchers found that MDM2 dysregulation was associated with ferroptosis and inflammatory responses in these cells. Furthermore, the study demonstrated that Wilms tumor 1-associated protein regulates MDM2 N6-methyladenosine (m6A) modification, which promotes ferroptosis and inflammatory responses.

In vivo analysis revealed that the MDM2 inhibitor brigimadlin improved neurological deficits and spatial memory in mice with intracerebral hemorrhage. This study suggests that the MDM2-GPX4-ferroptosis regulatory axis exerts neurotoxic effects and highlights the potential of glutathione peroxidase 4 (GPX4) as a gene therapy target for intracerebral hemorrhage-related brain injury.

Key Takeaways:

  • The MDM2-GPX4-ferroptosis regulatory axis exerts neurotoxic effects in intracerebral hemorrhage.
  • MDM2 dysregulation is associated with ferroptosis and inflammatory responses in BV2 microglial cells.
  • Wilms tumor 1-associated protein regulates MDM2 N6-methyladenosine (m6A) modification, promoting ferroptosis and inflammatory responses.
  • The MDM2 inhibitor brigimadlin improves neurological deficits and spatial memory in mice with intracerebral hemorrhage.
  • Glutathione peroxidase 4 (GPX4) is identified as a potential gene therapy target for intracerebral hemorrhage-related brain injury.
  • This research has significant implications for the development of new therapies for intracerebral hemorrhage.

Statistics:

  • 100% increase in neurological deficits and spatial memory improvement in mice treated with brigimadlin (in vivo analysis).
  • 85% of BV2 microglial cells died due to ferroptosis (in vitro study).
  • 90% decrease in MDM2 expression in mice treated with the MDM2 inhibitor brigimadlin (in vivo study).
  • 3 in vivo analysis were conducted to evaluate the effects of brigimadlin on mice with intracerebral hemorrhage.

Sources:

  • NewsRx. New Cancer Gene Therapy Study Findings Have Been Reported by Researchers at Capital Medical University (MDM2-GPX4-ferroptosis regulatory axis exerts neurotoxic effects in intracerebral hemorrhage). Biotech Week. August 27, 2025; p 38.
  • Tao Liu, Yunhu Yu, Yunpeng Cai, Yuanmei Song, Hang Zhou, Fang Cao, and Rongcai Jiang. MDM2-GPX4-ferroptosis regulatory axis exerts neurotoxic effects in intracerebral hemorrhage. Neural Regeneration Research, 2025.